Skip to main content
. 2020 Nov 30;11(11):1022. doi: 10.1038/s41419-020-03223-0

Fig. 7. ZD55-IL-24 inhibits melanoma growth in B16-bearing immune-competent mouse model also through inhibiting angiogenesis.

Fig. 7

A, B Changes of the angiogenesis-related cytokines in tumors treated with ZD55-IL-24. A Heat-map of the down-regulated pro-angiogenic cytokines in Fig. 2C. B Heat-map of the up-regulated anti-angiogenic cytokines in Fig. 2D. C, D The anti-angiogenic effect of ZD55-IL-24 in vitro. C The murine vascular endothelial bEnd.3 cells were infected with ZD55-IL-24 at a series of MOI (PFU/cell) from 0 to 150, the appearance of cytopathic effect was monitored under microscope, and representative photographs were taken at day 4 post-infection D and cell viability was measured by CCK-8 assay. Results represent mean ± SEM of triplicate experiments and are expressed as a percentage of control cells. E, F The anti-angiogenic effect of ZD55-IL-24 in vivo. Tumors resected from B16-bearing C57BL/6 mice receiving PBS or ZD55-IL-24 treatment indicated in Fig. 1A were analyzed 2 days after the last injection by immunohistochemical staining. E Representative images of tumor sections immunostained for the endothelial marker CD31 (green) to label the blood vessels in tumors. F Quantification of the CD31+ cells in E (n = 9). Nuclei is counterstained with DAPI (blue). P PBS, Z ZD55-IL-24. Scale bars, 300 µm. Data are mean ± SD. Shown is one of three independent experiments.